Metformin Hydrochloride Extended-Release Tablets 500 mg and 750 mg

Creekwood Pharmaceuticals LLC

Revision date : 2024-08-14

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS07
Health risk rating 3
Safety risk rating 1
Environmental risk rating 1

General Information

Revision date

2024-08-14

Product name

Metformin Hydrochloride Extended-Release Tablets 500 mg and 750 mg

CAS No.

1115-70-4

1.2.1 Relevant identified uses

Oral

Icons in SDS

GHS07 M010 M011

Company Information

company name

Creekwood Pharmaceuticals LLC

e-mail address of the competent person responsible for the Safety Data Sheet

sujit@creekwoodpharma.com

GHS Information

Signal word

Warning

Hazard Codes

Hazard statements (CLP)

H302, H315, H320

Hazard statements

Code

Statements

H302

Harmful if swallowed

H315

Causes skin irritation

H320

Causes eye irritation

Section 2

SECTION 2: Hazards identification

Physical hazards

Not classified

Health hazards

Acute toxicity, oral Category 4 Eye irritation Category 2 Skin irritation Category 2

Signal word

Warning

Hazard statements

Harmful if swallowed. Causes eye irritation. Causes skin irritation. May be harmful by inhalation. Fire and Explosion Assume that this product is capable of sustaining combustion. Health Metformin is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. Known hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin. Metformin should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function.

Environmental hazards

No information is available about the potential of this product to produce adverse environmental effects.

Prevention

Wash face, hands and any exposed skin thoroughly after handling Do not eat, drink or smoke when using this product Wear protective gloves/protective clothing/eye protection/face protection Avoid breathing dust/fume/gas/mist/vapors/spray Use only outdoors or in a well-ventilated area

Response

IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. Rinse mouth. If skin irritation occurs: Get medical advice/attention. If eye irritation persists: Get medical advice/attention. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/physician if you feel unwell. Storage and Disposal Please refer to Section 7 for Storage and Section 13 for Disposal information.

2.3 Other hazards

None identified.

2.1 Classification of the substance or mixture

Not classified Health hazards Acute toxicity, oral Category 4 Eye irritation Category 2 Skin irritation

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.